The regulatory network of the chemokine CCL5 in colorectal cancer

Abstract The chemokine CCL5 plays a potential role in the occurrence and development of colorectal cancer (CRC). Previous studies have shown that CCL5 directly acts on tumor cells to change tumor metastatic rates. In addition, CCL5 recruits immune cells and immunosuppressive cells into the tumor microenvironment (TME) and reshapes the TME to adapt to tumor growth or increase antitumor immune efficacy, depending on the type of secretory cells releasing CCL5, the cellular function of CCL5 recruitment, and the underlying mechanisms. However, at present, research on the role played by CCL5 in the occurrence and development of CRC is still limited, and whether CCL5 promotes the occurrence and development of CRC and its role remain controversial. This paper discusses the cells recruited by CCL5 in patients with CRC and the specific mechanism of this recruitment, as well as recent clinical studies of CCL5 in patients with CRC. Key Messages CCL5 plays dual roles in colorectal cancer progression. CCL5 remodels the tumor microenvironment to adapt to colorectal cancer tumor growth by recruiting immunosuppressive cells or by direct action. CCL5 inhibits colorectal cancer tumor growth by recruiting immune cells or by direct action.

[1]  H. Leavis,et al.  CCL5 Release by CCR9+ CD8 T Cells: A Potential Contributor to Immunopathology of Primary Sjögren’s Syndrome , 2022, Frontiers in Immunology.

[2]  M. Cristofanilli,et al.  CCR5 activation and endocytosis in circulating tumor-derived cells isolated from the blood of breast cancer patients provide information about clinical outcome , 2022, Breast cancer research : BCR.

[3]  Z. Yao,et al.  Cancer associated fibroblast–derived CCL5 promotes hepatocellular carcinoma metastasis through activating HIF1α/ZEB1 axis , 2022, Cell Death & Disease.

[4]  Zhongying Zhao,et al.  mTOR Signaling Pathway Regulates the Release of Proinflammatory Molecule CCL5 Implicated in the Pathogenesis of Autism Spectrum Disorder , 2022, Frontiers in Immunology.

[5]  Zhi-yan Hu,et al.  Tumor bud-derived CCL5 recruits fibroblasts and promotes colorectal cancer progression via CCR5-SLC25A24 signaling , 2022, Journal of experimental & clinical cancer research : CR.

[6]  A. Jemal,et al.  Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.

[7]  R. M. Simpson,et al.  CCL5 production in lung cancer cells leads to an altered immune microenvironment and promotes tumor development , 2021, Oncoimmunology.

[8]  L. Tian,et al.  Macrophages-aPKCɩ-CCL5 Feedback Loop Modulates the Progression and Chemoresistance in Cholangiocarcinoma , 2021, Journal of Experimental & Clinical Cancer Research.

[9]  Weigang Zhang,et al.  hsa_circ_0003410 promotes hepatocellular carcinoma progression by increasing the ratio of M2/M1 macrophages through the miR‐139‐3p/CCL5 axis , 2021, Cancer science.

[10]  J. Moreaux,et al.  The microenvironment of DLBCL is characterized by noncanonical macrophages recruited by tumor-derived CCL5 , 2021, Blood advances.

[11]  E. Mackow,et al.  Blockade of Autocrine CCL5 Responses Inhibits Zika Virus Persistence and Spread in Human Brain Microvascular Endothelial Cells , 2021, mBio.

[12]  P. Zhao,et al.  Depiction of the genomic and genetic landscape identifies CCL5 as a protective factor in colorectal neuroendocrine carcinoma , 2021, British Journal of Cancer.

[13]  J. V. van Roon,et al.  Transcriptome Analysis of CCR9+ T Helper Cells From Primary Sjögren’s Syndrome Patients Identifies CCL5 as a Novel Effector Molecule , 2021, Frontiers in Immunology.

[14]  Peng Chen,et al.  Tumor‐associated macrophage‐derived CCL5 promotes chemotherapy resistance and metastasis in prostatic cancer , 2021, Cell biology international.

[15]  S. Zelenay,et al.  DNGR-1 limits Flt3L-mediated antitumor immunity by restraining tumor-infiltrating type I conventional dendritic cells , 2021, Journal for ImmunoTherapy of Cancer.

[16]  Takashi Suzuki,et al.  Stromal CCL5 Promotes Breast Cancer Progression by Interacting with CCR3 in Tumor Cells , 2021, International journal of molecular sciences.

[17]  B. Van Houten,et al.  The Multiple Cellular Roles of SMUG1 in Genome Maintenance and Cancer , 2021, International journal of molecular sciences.

[18]  Shan Xu,et al.  CCL5-dependent mast cell infiltration into the tumor microenvironment in clear cell renal cell carcinoma patients , 2020, Aging.

[19]  Yibin Kang,et al.  E-cigarette promotes breast carcinoma progression and lung metastasis: Macrophage-tumor cells crosstalk and the role of CCL5 and VCAM-1. , 2020, Cancer letters.

[20]  A. Rotter,et al.  CCR5-Mediated Signaling is Involved in Invasion of Glioblastoma Cells in Its Microenvironment , 2020, International journal of molecular sciences.

[21]  F. Rojo,et al.  Autocrine CCL5 Effect Mediates Trastuzumab Resistance by ERK Pathway Activation in HER2-Positive Breast Cancer , 2020, Molecular Cancer Therapeutics.

[22]  Á. Vicente,et al.  Platelet Toll-Like Receptors Mediate Thromboinflammatory Responses in Patients With Essential Thrombocythemia , 2020, Frontiers in Immunology.

[23]  Xunbin Wei,et al.  PD-L1 is a direct target of cancer-FOXP3 in pancreatic ductal adenocarcinoma (PDAC), and combined immunotherapy with antibodies against PD-L1 and CCL5 is effective in the treatment of PDAC , 2020, Signal Transduction and Targeted Therapy.

[24]  Shengqi Wang,et al.  CCL5 derived from tumor-associated macrophages promotes prostate cancer stem cells and metastasis via activating β-catenin/STAT3 signaling , 2020, Cell Death & Disease.

[25]  T. Kohwi-Shigematsu,et al.  Runx-mediated regulation of CCL5 via antagonizing two enhancers influences immune cell function and anti-tumor immunity , 2020, Nature Communications.

[26]  Haibao Zhang,et al.  Cutaneous neurofibroma cells with active YAP promotes proliferation of macrophages resulting in increased accumulation of macrophages by modulating CCL5 and TGF‑β1. , 2020, Oncology reports.

[27]  Bangshun He,et al.  Correction: Macrophage-derived CCL5 facilitates immune escape of colorectal cancer cells via the p65/STAT3-CSN5-PD-L1 pathway , 2020, Cell Death and Differentiation.

[28]  Jungsook Cho,et al.  Chemokines and their Receptors: Multifaceted Roles in Cancer Progression and Potential Value as Cancer Prognostic Markers , 2020, Cancers.

[29]  R. Khokha,et al.  A Four-Chemokine Signature Is Associated with a T-cell–Inflamed Phenotype in Primary and Metastatic Pancreatic Cancer , 2020, Clinical Cancer Research.

[30]  M. Üçüncü,et al.  The Diagnostic Significance of PDGF, EphA7, CCR5, and CCL5 Levels in Colorectal Cancer , 2019, Biomolecules.

[31]  S. Moestrup,et al.  Specific targeting of CD163+ TAMs mobilizes inflammatory monocytes and promotes T cell–mediated tumor regression , 2019, The Journal of experimental medicine.

[32]  D. Jackson,et al.  Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. , 2019, Cancer cell.

[33]  Ming Yan,et al.  APOBEC3B interaction with PRC2 modulates microenvironment to promote HCC progression , 2019, Gut.

[34]  D. Aldinucci,et al.  Formation of the Immunosuppressive Microenvironment of Classic Hodgkin Lymphoma and Therapeutic Approaches to Counter It , 2019, International journal of molecular sciences.

[35]  Qingqin Sun,et al.  Identification of a novel biomarker-CCL5 using antibody microarray for colorectal cancer. , 2019, Pathology, research and practice.

[36]  Y. Sakai,et al.  Bone marrow-derived mesenchymal stem cells promote colorectal cancer progression via CCR5 , 2019, Cell death & disease.

[37]  Mengyu Guo,et al.  Tailoring Nanomaterials for Targeting Tumor‐Associated Macrophages , 2019, Advanced materials.

[38]  Brian Ruffell,et al.  Macrophages as regulators of tumour immunity and immunotherapy , 2019, Nature Reviews Immunology.

[39]  A. Barzi,et al.  Genetic variants in CCL5 and CCR5 genes and serum VEGF‐A levels predict efficacy of bevacizumab in metastatic colorectal cancer patients , 2018, International journal of cancer.

[40]  A. Barzi,et al.  Role of CCL5 and CCR5 gene polymorphisms in epidermal growth factor receptor signalling blockade in metastatic colorectal cancer: analysis of the FIRE-3 trial. , 2019, European journal of cancer.

[41]  B. Molon,et al.  Chemokines and Chemokine Receptors: Orchestrating Tumor Metastasization , 2018, International journal of molecular sciences.

[42]  A. Kawada,et al.  CCR4 Is Critically Involved in Skin Allergic Inflammation of BALB/c Mice. , 2018, The Journal of investigative dermatology.

[43]  X. Breakefield,et al.  Multidimensional communication in the microenvirons of glioblastoma , 2018, Nature Reviews Neurology.

[44]  Wei-Qiang Gao,et al.  CCL5-deficiency enhances intratumoral infiltration of CD8+ T cells in colorectal cancer , 2018, Cell Death & Disease.

[45]  Jia Luo,et al.  Alcohol consumption promotes colorectal carcinoma metastasis via a CCL5-induced and AMPK-pathway-mediated activation of autophagy , 2018, Scientific Reports.

[46]  A. Barzi,et al.  Gene Polymorphisms in the CCL5/CCR5 Pathway as a Genetic Biomarker for Outcome and Hand–Foot Skin Reaction in Metastatic Colorectal Cancer Patients Treated With Regorafenib , 2018, Clinical colorectal cancer.

[47]  D. Aldinucci,et al.  Inhibition of the CCL5/CCR5 Axis against the Progression of Gastric Cancer , 2018, International journal of molecular sciences.

[48]  Amy R. Peck,et al.  CCR5 Governs DNA Damage Repair and Breast Cancer Stem Cell Expansion. , 2018, Cancer research.

[49]  E. Sahai,et al.  NK Cells Stimulate Recruitment of cDC1 into the Tumor Microenvironment Promoting Cancer Immune Control , 2018, Cell.

[50]  V. Arolt,et al.  The C-C Chemokines CCL17 and CCL22 and Their Receptor CCR4 in CNS Autoimmunity , 2017, International journal of molecular sciences.

[51]  N. Waddell,et al.  Interleukin-12 from CD103+ Batf3-Dependent Dendritic Cells Required for NK-Cell Suppression of Metastasis , 2017, Cancer Immunology Research.

[52]  Zhou-Ji Zhang,et al.  Down-regulation of KLF5 in cancer-associated fibroblasts inhibit gastric cancer cells progression by CCL5/CCR5 axis , 2017, Cancer biology & therapy.

[53]  M. Ferrari,et al.  Targeting Autocrine CCL5-CCR5 Axis Reprograms Immunosuppressive Myeloid Cells and Reinvigorates Antitumor Immunity. , 2017, Cancer research.

[54]  Weiping Zou,et al.  Chemokines in the cancer microenvironment and their relevance in cancer immunotherapy , 2017, Nature Reviews Immunology.

[55]  Daniel M. Corey,et al.  PD-1 expression by tumor-associated macrophages inhibits phagocytosis and tumor immunity , 2017, Nature.

[56]  Ke Chen,et al.  Human MSCs promotes colorectal cancer epithelial–mesenchymal transition and progression via CCL5/β-catenin/Slug pathway , 2017, Cell Death and Disease.

[57]  D. He,et al.  Infiltrating mast cells promote renal cell carcinoma angiogenesis by modulating PI3K→AKT→GSK3β→AM signaling , 2017, Oncogene.

[58]  S. Yang,et al.  Cancer-FOXP3 directly activated CCL5 to recruit FOXP3+Treg cells in pancreatic ductal adenocarcinoma , 2016, Oncogene.

[59]  K. Rogers,et al.  Cancer cell CCL5 mediates bone marrow independent angiogenesis in breast cancer , 2016, Oncotarget.

[60]  M. Karin,et al.  Autophagy, Inflammation, and Immunity: A Troika Governing Cancer and Its Treatment , 2016, Cell.

[61]  F. Ginhoux,et al.  Expansion and Activation of CD103(+) Dendritic Cell Progenitors at the Tumor Site Enhances Tumor Responses to Therapeutic PD-L1 and BRAF Inhibition. , 2016, Immunity.

[62]  M. Koch,et al.  Tumoral Immune Cell Exploitation in Colorectal Cancer Metastases Can Be Targeted Effectively by Anti-CCR5 Therapy in Cancer Patients. , 2016, Cancer cell.

[63]  V. Bronte,et al.  Interfering with CCL5/CCR5 at the Tumor-Stroma Interface. , 2016, Cancer cell.

[64]  L. Marti,et al.  Chemokines and immunity , 2015, Einstein.

[65]  J. Hung,et al.  Chemokine (C‐C Motif) Ligand 5 is Involved in Tumor‐Associated Dendritic Cell‐Mediated Colon Cancer Progression Through Non‐Coding RNA MALAT‐1 , 2015, Journal of cellular physiology.

[66]  G. Böning,et al.  Mesenchymal Stem Cell–Mediated, Tumor Stroma–Targeted Radioiodine Therapy of Metastatic Colon Cancer Using the Sodium Iodide Symporter as Theranostic Gene , 2015, The Journal of Nuclear Medicine.

[67]  B. Montanini,et al.  Transcriptomic Analysis of Human Polarized Macrophages: More than One Role of Alternative Activation? , 2015, PloS one.

[68]  A. Goel,et al.  Active secretion of CXCL10 and CCL5 from colorectal cancer microenvironments associates with GranzymeB+ CD8+ T-cell infiltration , 2014, Oncotarget.

[69]  Hui-Lung Sun,et al.  CCL5/CCR5 axis induces vascular endothelial growth factor-mediated tumor angiogenesis in human osteosarcoma microenvironment. , 2015, Carcinogenesis.

[70]  M. Colombo,et al.  The Role of Mast Cells in Molding the Tumor Microenvironment , 2015, Cancer Microenvironment.

[71]  Sebastian Amigorena,et al.  Dissecting the tumor myeloid compartment reveals rare activating antigen-presenting cells critical for T cell immunity. , 2014, Cancer cell.

[72]  G. Ranieri,et al.  Possible biological and translational significance of mast cells density in colorectal cancer. , 2014, World journal of gastroenterology.

[73]  R. Horuk,et al.  Recent progress in the development of antagonists to the chemokine receptors CCR3 and CCR4 , 2014, Expert opinion on drug discovery.

[74]  A. Luster,et al.  Chemokines and chemokine receptors: positioning cells for host defense and immunity. , 2014, Annual review of immunology.

[75]  J. Krstić,et al.  Transforming Growth Factor-Beta and Matrix Metalloproteinases: Functional Interactions in Tumor Stroma-Infiltrating Myeloid Cells , 2014, TheScientificWorldJournal.

[76]  E. Elinav,et al.  Microbiota-induced activation of epithelial IL-6 signaling links inflammasome-driven inflammation with transmissible cancer , 2013, Proceedings of the National Academy of Sciences.

[77]  Xiaojing Ma,et al.  CCL5 as a potential immunotherapeutic target in triple-negative breast cancer , 2013, Cellular and Molecular Immunology.

[78]  Xiaojing Ma,et al.  A novel role of hematopoietic CCL5 in promoting triple-negative mammary tumor progression by regulating generation of myeloid-derived suppressor cells , 2012, Cell Research.

[79]  Takuji Tanaka,et al.  Mast cells and inflammation-associated colorectal carcinogenesis , 2013, Seminars in Immunopathology.

[80]  Lixin Wei,et al.  One cell, multiple roles: contribution of mesenchymal stem cells to tumor development in tumor microenvironment , 2013, Cell & Bioscience.

[81]  A. Viola,et al.  The pros and cons of chemokines in tumor immunology. , 2012, Trends in immunology.

[82]  Sheng Lin,et al.  Autocrine CCL5 Signaling Promotes Invasion and Migration of CD133+ Ovarian Cancer Stem‐Like Cells via NF‐κB‐Mediated MMP‐9 Upregulation , 2012, Stem cells.

[83]  Takuji Tanaka,et al.  Mast cells and inflammation-associated colorectal carcinogenesis , 2012, Seminars in Immunopathology.

[84]  M. Lisanti,et al.  CCR5 antagonist blocks metastasis of basal breast cancer cells. , 2012, Cancer research.

[85]  M. Moriyama,et al.  Cytokine/chemokine profiles contribute to understanding the pathogenesis and diagnosis of primary Sjögren's syndrome , 2012, Clinical and experimental immunology.

[86]  David C. Smith,et al.  Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. , 2012, The New England journal of medicine.

[87]  C. Sautès-Fridman,et al.  The immune contexture in human tumours: impact on clinical outcome , 2012, Nature Reviews Cancer.

[88]  J. Chiang,et al.  Tumor-Derived Chemokine CCL5 Enhances TGF- b – Mediated Killing of CD8 þ T Cells in Colon Cancer by T-Regulatory Cells , 2012 .

[89]  B. Pitard,et al.  CCL5 Neutralization Restricts Cancer Growth and Potentiates the Targeting of PDGFRβ in Colorectal Carcinoma , 2011, PloS one.

[90]  G. Dranoff,et al.  Cancer immunology—analysis of host and tumor factors for personalized medicine , 2011, Nature Reviews Clinical Oncology.

[91]  J. Pease.  Targeting chemokine receptors in allergic disease. , 2011, The Biochemical journal.

[92]  P. Carmeliet,et al.  HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. , 2011, Cancer cell.

[93]  M. Kerin,et al.  Mesenchymal stem cells and cancer: tumor-specific delivery vehicles or therapeutic targets? , 2010, Human gene therapy.

[94]  K. Clément,et al.  CCL5 Promotes Macrophage Recruitment and Survival in Human Adipose Tissue , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[95]  A. IJzerman,et al.  Small molecule antagonists for chemokine CCR3 receptors , 2009, Medicinal research reviews.

[96]  R. Schwabe,et al.  CCR1 and CCR5 promote hepatic fibrosis in mice. , 2009, The Journal of clinical investigation.

[97]  S. Rasmussen,et al.  The structure and function of G-protein-coupled receptors , 2009, Nature.

[98]  J. Pollard,et al.  Microenvironmental regulation of metastasis , 2009, Nature Reviews Cancer.

[99]  L. Rollins,et al.  Targeting the Intratumoral Dendritic Cells by the Oncolytic Adenoviral Vaccine Expressing RANTES Elicits Potent Antitumor Immunity , 2009, Journal of immunotherapy.

[100]  S. Kaneko,et al.  Chemokine Receptor CCR1 Regulates Inflammatory Cell Infiltration after Renal Ischemia-Reperfusion Injury1 , 2008, The Journal of Immunology.

[101]  Christian Weber,et al.  Chemokines in Atherosclerosis , Thrombosis , and Vascular Biology Series Editor : Christian Weber Chemokines in Atherosclerosis An Update , 2008 .

[102]  A. Ben-Baruch,et al.  The inflammatory chemokines CCL2 and CCL5 in breast cancer. , 2008, Cancer letters.

[103]  M. Kinoshita,et al.  Gastric cancer cells exploit CD4+ cell‐derived CCL5 for their growth and prevention of CD8+ cell‐involved tumor elimination , 2008, International journal of cancer.

[104]  Ryuzo Ueda,et al.  CCR4 as a novel molecular target for immunotherapy of cancer , 2006, Cancer science.

[105]  A. Purandare,et al.  Antagonists of CCR4 as immunomodulatory agents. , 2006, Current topics in medicinal chemistry.

[106]  L. Coussens,et al.  Tumor stroma and regulation of cancer development. , 2006, Annual review of pathology.

[107]  Xiaojing Ma,et al.  Interferon Regulatory Factor 1 Is an Essential and Direct Transcriptional Activator for Interferon γ-induced RANTES/CCl5 Expression in Macrophages* , 2005, Journal of Biological Chemistry.

[108]  N. Fusenig,et al.  Friends or foes — bipolar effects of the tumour stroma in cancer , 2004, Nature Reviews Cancer.

[109]  E. Eriksson.  Mechanisms of leukocyte recruitment to atherosclerotic lesions: future prospects , 2004, Current opinion in lipidology.

[110]  K. Sheppard,et al.  PD‐1 inhibits T‐cell receptor induced phosphorylation of the ZAP70/CD3ζ signalosome and downstream signaling to PKCθ , 2004 .

[111]  F. Balkwill.  Cancer and the chemokine network , 2004, Nature Reviews Cancer.

[112]  K. Sheppard,et al.  PD-1 inhibits T-cell receptor induced phosphorylation of the ZAP70/CD3zeta signalosome and downstream signaling to PKCtheta. , 2004, FEBS letters.

[113]  A. Trkola,et al.  RANTES (CCL5) uses the proteoglycan CD44 as an auxiliary receptor to mediate cellular activation signals and HIV-1 enhancement. , 2003, Blood.

[114]  F. Balkwill,et al.  Chemokine stimulation of monocyte matrix metalloproteinase‐9 requires endogenous TNF‐α  , 2002, European journal of immunology.

[115]  A. Iellem,et al.  Unique Chemotactic Response Profile and Specific Expression of Chemokine Receptors Ccr4 and Ccr8 by Cd4+Cd25+ Regulatory T Cells , 2001, The Journal of experimental medicine.

[116]  R. Horuk,et al.  Specialized roles of the chemokine receptors CCR1 and CCR5 in the recruitment of monocytes and T(H)1-like/CD45RO(+) T cells. , 2001, Blood.

[117]  B. Rollins,et al.  Chemokines and disease , 2001, Nature Immunology.

[118]  C. Bertrand,et al.  CCR3 blockade as a new therapy for asthma , 2000, Expert opinion on investigational drugs.

[119]  D. Hanahan,et al.  Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. , 1999, Genes & development.

[120]  J. Farber,et al.  Chemokine receptors as HIV-1 coreceptors: roles in viral entry, tropism, and disease. , 1999, Annual review of immunology.

[121]  T. Schall,et al.  A human T cell-specific molecule is a member of a new gene family. , 1988, Journal of immunology.